David Alberts
Chief Tech/Sci/R&D Officer at Omnitura Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Dao | M | - |
Omnitura Therapeutics, Inc.
 Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | 23 years |
| Francis V. Dane | M | 71 |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | 23 years |
| James Dao | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | 23 years |
| Peter W. Likins | M | 87 |
University of Arizona
| 27 years |
| Norman P. McClelland | M | - |
University of Arizona
| - |
| Ann Weaver Hart | M | 74 |
University of Arizona
| 12 years |
| Jerry R. Norskog | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
| Simon Sutcliffe | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | 15 years |
| Michael E. Hogan | M | - |
University of Arizona
| - |
| Keith Runge | M | - |
University of Arizona
| - |
| Joshua Johnson | M | 44 |
University of Arizona
| - |
| Stephen M. Papadopoulos | M | - |
University of Arizona
| - |
| Jennifer Casteix | F | - |
University of Arizona
| - |
| Jamie Gutierrez | M | - |
University of Arizona
| - |
| Douglas Taren | M | - |
University of Arizona
| - |
| Christopher M. Hopkins | M | - |
University of Arizona
| - |
| Edward H. Shortliffe | M | 76 |
University of Arizona
| 17 years |
| Vikki Dempsey | F | - |
University of Arizona
| - |
| Ronald J. Richman | M | 82 |
University of Arizona
| 16 years |
| Ivo Abraham | M | - |
University of Arizona
| - |
| Doo-Hwan Kim | M | - |
University of Arizona
| - |
| Stephen Lam | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
| Bernard Zeigler | M | - |
University of Arizona
| - |
| Rodney C. Armstead | M | - |
University of Arizona
| - |
| Teresa Briggs | F | 63 |
University of Arizona
| - |
| Barbara K. Cone | M | - |
University of Arizona
| - |
| David Smallhouse | M | - |
University of Arizona
| - |
| Anthony D. Puopolo | M | 52 |
University of Arizona
| - |
| Sarah Netherton | F | - |
University of Arizona
| - |
| Meg Hagyard | F | - |
University of Arizona
| - |
| Ruth Zollinger | F | - |
University of Arizona
| - |
| Eileen McGarry | F | - |
University of Arizona
| - |
| Robert Lopez-Hanshaw | M | - |
University of Arizona
| - |
| Kevin M. Fitzsimmons | M | 67 |
University of Arizona
| 43 years |
| Larry Goldenberg | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
| Nasser Peyghambarian | M | - |
University of Arizona
| - |
| James B. Fink | M | - |
University of Arizona
| - |
| Martin P. Fox | M | - |
University of Arizona
| - |
| Sylvia C. Quintero | F | 65 |
University of Arizona
| - |
| Joaquin Ruiz | M | 71 |
University of Arizona
| 41 years |
| Thomas M. Grogan | M | 78 |
University of Arizona
| 45 years |
| Elaine L. Jacobson | M | - |
University of Arizona
| - |
| Myron K. Jacobson | M | - |
University of Arizona
| - |
| David Morris Korbin | M | 82 |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
| Steven Barker | M | 79 |
University of Arizona
| - |
| Daniel Douglas von Hoff | M | 76 |
University of Arizona
| - |
| Juha Tapani Rantala | M | - |
University of Arizona
| - |
| Kerstin Block | F | - |
University of Arizona
| 18 years |
| Jack Troia | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
| Mark Lautman | M | - |
University of Arizona
| - |
| Ross MacLean | M | - |
University of Arizona
| - |
| Christine Spiegelberg | M | - |
University of Arizona
| - |
| Augusto Sasso | M | - |
University of Arizona
| - |
| Stephen Golden | M | - |
University of Arizona
| - |
| Barry A. Hendin | M | - |
University of Arizona
| - |
| Tom E. McCandless | M | 69 |
University of Arizona
| - |
| L. Ben Lytle | M | 77 |
University of Arizona
| - |
| Dwight Babcock | M | 76 |
University of Arizona
| - |
| Marvin Slepian | M | 68 |
University of Arizona
| 33 years |
| Kenneth Foon | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
| Sara Garre | F | - |
University of Arizona
| 5 years |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 61 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Alberts
- Personal Network
